

Guidance to Liver Transplant Programs and the National Liver Review Board for: Adult MELD Exceptions for Hepatocellular Carcinoma (HCC)

Background

A liver candidate receives a MELD¹ or, if less than 12 years old, a PELD² score that is used for liver allocation. The score is intended to reflect the candidate's disease severity, or the risk of 3-month mortality without access to liver transplant. When the calculated score does not reflect the candidate's medical urgency, a liver transplant program may request an exception score. A candidate that meets the criteria for one of nine diagnoses in policy is approved for a standardized MELD exception.³ If the candidate does not meet criteria for standardized exception, the request is considered by the Review Board.

The OPTN Liver and Intestinal Organ Transplantation Committee (hereafter, "the Committee") has developed guidance for adult MELD exceptions for Hepatocellular Carcinoma (HCC). This guidance document is intended to provide recommendations for the review board considering HCC cases which are outside standard policy.

This guidance replaces any independent criteria that OPTN regions used to request and approve exceptions, commonly referred to as "regional agreements." Review board members and transplant centers should consult this resource when considering MELD exception requests for adult candidates with the following diagnoses.

Recommendation

1. Patients with the following are contraindications for HCC exception score:
 - Macro-vascular invasion of main portal vein or hepatic vein
 - Extra-hepatic metastatic disease
 - Ruptured HCC
 - T1 stage HCC

While in most cases, ruptured HCC and primary portal vein branch invasion of HCC would be contraindications, some patients who remain stable for a prolonged (minimum of 12 months) interval after treatment for primary portal vein branch invasion or after ruptured HCC may be suitable for consideration.

1. Patients who have a history of prior HCC more than 2 years ago which was completely treated with no evidence of recurrence, who develop new or recurrent lesions after 2 years should

¹Model for End-Stage Liver Disease

²Pediatric End-Stage Liver Disease

³Policy 9.3.C: Specific MELD/PELD Exceptions, Organ Procurement and Transplantation Network Policies.

generally be considered the same as those with no prior HCC, in order to determine the current stage suitability for an initial MELD exception, and initial MELD exception score assignment.

2. Patients beyond standard criteria who have continued progression while waiting despite LRT are generally not acceptable candidates for HCC MELD exception.
3. Patients with AFP>1000 who do not respond to treatment to achieve an AFP below 500 are not eligible for standard MELD exception, and must be reviewed by the HCC review board to be considered. In general, these patients are not suitable for HCC MELD exception but may be appropriate in some cases.
4. Patients with HCC beyond standard down-staging criteria who are able to be successfully downstaged to T2 may be appropriate for MELD exception, as long as there is no evidence of metastasis outside the liver, or macrovascular invasion, or AFP >1,000. Imaging should be performed at least 4 weeks after last down-staging treatment. Patients must still wait for 6 months from the time of the first request to be eligible for an HCC exception score.
5. Patients with cirrhosis who presented with stage T2 resectable HCC (one lesion >2 cm and <5 cm in size, or two or three lesions >1 cm and <3 cm in size, based on resection specimen pathology) who underwent complete resection but developed T1 (biopsy proven), or T2 HCC (LI-RADS 5) following complete resection should be considered for MELD score exception, without a six month delay period.

Patients with cirrhosis and HCC beyond T2 but within generally accepted criteria for down-staging (such as up to 5 lesions, total tumor volume <8 cm based on resection pathology) who underwent complete resection with negative margins and developed T1 (biopsy proven) or T2 recurrence (LI-RADS 5) may also be considered for MELD score exception for HCC. Because the larger tumor size, the 6 month delay is appropriate to ensure favorable tumor biology.

Recommendations for Dynamic Contrast-enhanced CT or MRI of the Liver

Table 1: Recommendations for Dynamic Contrast-enhanced CT of the Liver

Feature:	CT scans should meet the below specifications:
Scanner type	Multidetector row scanner
Detector type	Minimum of 8 detector rows and must be able to image the entire liver during brief late arterial phase time window
Slice thickness	Minimum of 5 mm reconstructed slice thickness; thinner slices are preferable especially if multiplanar reconstructions are performed
Injector	Power injector, preferably dual chamber injector with saline flush and bolus tracking recommended
Contrast injection rate	3 mL/sec minimum, better 4-6 mL/sec with minimum of 300 mg I/mL or higher, for dose of 1.5 mL/kg body weight

Feature:	CT scans should meet the below specifications:
Mandatory dynamic phases on contrast-enhanced MDCT	<ol style="list-style-type: none"> 1. Late arterial phase: artery fully enhanced, beginning contrast enhancement of portal vein 2. Portal venous phase: portal vein enhanced, peak liver parenchymal enhancement, beginning contrast enhancement of hepatic veins 3. Delayed phase: variable appearance, greater than 120 seconds after initial injection of contrast
Dynamic phases (Timing)	Use the bolus tracking or timing bolus

Table 2: Recommendations for Dynamic Contrast-enhanced MRI of the Liver

Feature	MRIs should meet the below specifications:
Scanner type	1.5T Tesla or greater main magnetic field strength. Low field magnets are not suitable.
Coil type	Phased array multichannel torso coil, unless patient-related factors precludes its use.
Minimum sequences	Pre-contrast and dynamic post gadolinium T1-weighted gradient echo sequence (3D preferable), T2 (with and without fat saturation), T1-weighted in and out of phase imaging.
Injector	Dual chamber power injector with bolus tracking recommended.
Contrast injection rate	2-3 mL/sec of extracellular gadolinium chelate that does not have dominant biliary excretion, preferably resulting in vendor-recommended total dose.
Mandatory dynamic phases on contrast-enhanced MRI	<ol style="list-style-type: none"> 1. Pre-contrast T1W: do not change scan parameters for post contrast imaging. 2. Late arterial phase: artery fully enhanced, beginning contrast enhancement of portal vein. 3. Portal venous phase: portal vein enhanced, peak liver parenchymal enhancement, beginning contrast enhancement of hepatic veins. 4. Delayed phase: variable appearance, greater than 120 seconds after initial injection of contrast.
Dynamic phases (Timing)	The use of the bolus tracking method for timing contrast arrival for late arterial phase imaging is preferable. Portal vein phase images should be acquired 35 to 55 seconds after initiation of late arterial phase. Delayed phase images should be acquired 120 to 180 seconds after the initial contrast injection.
Slice thickness	5 mm or less for dynamic series, 8 mm or less for other imaging.
Breath-holding	Maximum length of series requiring breath-holding should be about 20-seconds with a minimum matrix of 128 x 256. Technologists must understand the importance of patient instruction about breath-holding before and during scan.